Wegovy 2.4mg FlexTouch Pre Filled Pen

Wegovy 2.4mg FlexTouch Pre Filled Pen contains Semaglutide 2.4mg, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is used for chronic weight management, to reduce cardiovascular risk, and for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Benefits

Wegovy 2.4mg FlexTouch helps reduce appetite and calorie intake, supporting significant weight loss when combined with a reduced-calorie diet and increased physical activity. It also lowers the risk of major adverse cardiovascular events like heart attack and stroke in adults with established heart disease. For MASH, it aids in reducing liver inflammation and fat accumulation.

Uses and Indications

• Chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes, dyslipidemia).
• Reduction of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.
• Treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (stages F2–F3) in adults.
• Weight management in adolescents aged 12 years and above with obesity (BMI ≥95th percentile) and body weight >60 kg.

The Wegovy 2.4mg FlexTouch Pre Filled Pen contains:

• Semaglutide 2.4mg (active ingredient).
• Excipients: disodium phosphate dihydrate, sodium chloride, water for injection. Hydrochloric acid or sodium hydroxide may be added for pH adjustment.

Dosage and Administration

1. Wegovy 2.4mg FlexTouch is administered as a once-weekly subcutaneous injection. It should be given on the same day each week, at any time of day, with or without food.
2. Inject the solution under the skin in the abdomen, thigh, or upper arm. Rotate the injection site with each dose; do not inject into the same spot every time. Avoid injecting into muscle or a vein.
3. Treatment typically starts with a lower dose (0.25mg once weekly) and is gradually increased over 16 weeks to the recommended maintenance dose of 2.4mg once weekly. Always follow your doctor's prescribed dosing schedule.
4. The FlexTouch Pre Filled Pen is for single-use only and delivers a preset dose. The injection takes approximately 5-10 seconds; press the pen firmly against the skin until the yellow bar stops moving.
5. If a dose is missed and the next scheduled dose is more than 2 days (48 hours) away, administer it as soon as possible. If the next scheduled dose is less than 2 days away, skip the missed dose and continue with the next scheduled dose.

Storage and Disposal

• Store the Wegovy FlexTouch Pre Filled Pen in the refrigerator between 2°C to 8°C (36°F to 46°F) in its original carton to protect it from light.
• Do not freeze Wegovy. Discard the pen if it has been frozen.
• Before first use, an unopened pen can be stored at room temperature (8°C to 30°C / 46°F to 86°F) for up to 28 days.
• After first use, the pen can be stored either in the refrigerator (2°C to 8°C) or at room temperature (below 30°C / 86°F) for a maximum of 6 weeks.
• Keep out of reach of children. Dispose of used pens and needles in an FDA-cleared sharps disposal container.

Precautions and Safety

• Wegovy should not be used in combination with other semaglutide-containing products or any other GLP-1 receptor agonists.
• Patients with type 2 diabetes should have their blood glucose monitored prior to and during Wegovy treatment, as there is an increased risk of hypoglycemia, especially when used with insulin or sulfonylureas. Dose adjustments of concomitant medications may be necessary.
• There is a risk of acute pancreatitis and gallbladder problems (cholelithiasis). Discontinue Wegovy promptly if pancreatitis is suspected.
• Severe allergic reactions, including anaphylaxis and angioedema, have been reported. Seek immediate medical attention if such reactions occur.
• Dehydration due to gastrointestinal side effects (nausea, vomiting, diarrhea) can lead to kidney problems. Ensure adequate fluid intake.
• Patients with type 2 diabetes should be monitored for complications of diabetic retinopathy, as changes in vision may occur or worsen.
• Avoid injecting into skin that is tender, bruised, red, hard, or has scars or stretch marks.

Side Effects and Risks

• Very common side effects (affecting more than 1 in 10 people) include headache, nausea, vomiting, diarrhea, constipation, stomach pain, and feeling weak or tired. These often subside over time.
• Common side effects (affecting up to 1 in 10 people) include dizziness, upset stomach or indigestion, burping, gas, bloating, inflamed stomach (gastritis), heartburn, dry mouth, gallstones, hair loss, injection site reactions, and altered taste sensation.
• Serious side effects, though less common, can include acute pancreatitis, severe allergic reactions, gallbladder problems, dehydration leading to kidney issues, and worsening of diabetic retinopathy.

Disclaimer

Use this medicine only under the prescription and guidance of a qualified doctor or pharmacist.